Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of infringing on patents for its blockbuster obesity drug Wegovy. The Danish pharmaceutical giant claims Hims is selling knock-off versions of semaglutide, the active ingredient in both Wegovy and Ozempic. This marks a significant escalation in Novo's legal strategy, as the company shifts from targeting marketing practices to directly challenging product infringement.

Hims had recently abandoned plans to sell a copycat version of Wegovy, but Novo's lawsuit now targets both the scrapped pill and compounded injections mimicking its weight-loss treatments. The case represents the first time Novo has pursued patent infringement claims specifically for compounded semaglutide products. Under CEO Mike Doustdar's leadership, the company appears to be taking a more aggressive stance against competitors in the rapidly growing obesity drug market.

This legal battle comes as demand for weight-loss medications surges, with Wegovy and Ozempic becoming cultural phenomena. Novo's aggressive patent protection strategy could have significant implications for telehealth companies and compounding pharmacies looking to capitalize on the obesity drug boom. The outcome may reshape how these businesses approach marketing and selling alternative versions of popular medications.

Quick Fact: Novo Nordisk's Wegovy generated $3.4 billion in sales in 2023.